| Literature DB >> 17996308 |
Ross M Okamura1, Jane Lebkowski, Melinda Au, Catherine A Priest, Jerrod Denham, Anish S Majumdar.
Abstract
A major concern in the use of allotransplantation of human embryonic stem cell (hESC)-based therapies is the possibility of allogeneic rejection by the host's immune system. In this report, we determined the immunological properties of hESC-derived oligodendrocyte progenitor cells (OPC) that have the potential for clinical application for the treatment of patients with spinal cord injury. In vitro immunological studies suggest that hESC-derived OPCs are poor targets for both the innate and the adaptive human immune effector cells as well as resistant to lysis by anti-Neu5Gc antibodies. These results indicate that hESC-derived OPCs retain some of the unique immunological properties of the parental cell line from which they were differentiated.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17996308 DOI： 10.1016/j.jneuroim.2007.09.030
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478